STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism (DiET)

August 4, 2016 updated by: Diagnostica Stago
The purpose of this study is to demonstrate the ability of STA® Liatest® D-Di combined with a clinical pretest probability (PTP) to safely exclude pulmonary embolism (PE) or Deep Venous Thrombosis (DVT) in a 3 month follow-up.

Study Overview

Status

Completed

Detailed Description

The study population will be selected from prospective, consecutive ambulatory outpatients suspected of having venous thromboembolism.

These patients will first be evaluated using the Wells score:

  • patients with low or moderate pretest probability will be considered for D-dimer testing, those with D-dimer positive will be considered for an imaging procedure,
  • patients with high pretest probability will be considered for an imaging procedure.

Patients with "low or moderate" pretest probability and a negative D-Dimer result will be followed for 3 months to evaluate potential development of deep venous thrombosis and/or pulmonary embolism.

These patients will be contacted by phone 3 month after their first visit.

Study Type

Observational

Enrollment (Actual)

2040

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Montréal, Canada
        • Maisonneuve Rosemont Hospital
      • Dijon, France
        • University Hospital
      • Grenoble, France, 38043
        • University Hospital
      • Bologna, Italy
        • University Hospital
      • Milan, Italy
        • IRCCS H San Raffaele
      • Alicante, Spain
        • University Hospital
      • Soria, Spain
        • General Hospital
    • Illinois
      • Chicago, Illinois, United States, 60611
        • Northwestern Medical Center
    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Indiana University Health
    • Iowa
      • Iowa City, Iowa, United States, 52242
        • University of Iowa
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Massachusetts General Hospital
      • Boston, Massachusetts, United States, 02115
        • Brigham and Woman's Hosp
    • North Carolina
      • Greensboro, North Carolina, United States, 27401
        • Moses Cone Memorial Hospital
    • Ohio
      • Colombus, Ohio, United States, 43210
        • Univeristy Medical Center
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73104
        • Oklahoma Health Sciences Center
    • Pennsylvania
      • Allentown, Pennsylvania, United States, 18103
        • Lehigh Valley Hospital Health Network
    • South Carolina
      • Charleston, South Carolina, United States, 29403
        • Medical Center of South Carolina
    • Texas
      • Fort Worth, Texas, United States, 76104
        • Texas Health Fort Worth Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 80 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The study population will be recruited from prospective, consecutive, ambulatory outpatients (presenting at the emergency unit or outpatient clinic) suspected of having venous thromboembolism

Description

INCLUSION CRITERIA

  1. Patient is < 80 years old.
  2. Patient presenting at least one of these symptoms indicative of proximal DVT or PE:

    • symptoms for proximal DVT: leg pain, tenderness (discomfort through palpation), leg swelling, and /or edema,
    • symptoms for PE: hemoptysis, lung related chest pain, dyspnea.
  3. Patient provides written informed consent to participate in the study (or verbal no-opposition, as allowed by local regulations)
  4. Patient is willing to comply with specified follow-up evaluation at 3 months and can be contacted by telephone

EXCLUSION CRITERIA

  1. Patient presenting with a condition that may be associated with increased D-dimer levels, even in the absence of VTE, such as:

    • Fibrinolytic therapy within the previous seven (7) days,
    • Bone fracture or surgery (with general anesthesia longer than thirty (30) minutes) within the previous one (1) month,
    • Deep hematoma diagnosed by imaging techniques within the previous one (1) month,
    • Disseminated malignancies and active cancer (active cancer defined as: cancer for which therapeutic or palliative treatment is either ongoing at the time of enrolment or has stopped less than six (6) months before enrolment),
    • Sepsis, severe infections, pneumonia within the previous 1 month,
    • Known liver cirrhosis,
    • Pregnancy or post-partum within the previous 1 month,
    • Atherosclerotic vascular disease thrombosis within the previous 1month (e.g. myocardial infarction, stroke, coronary syndrome, peripheral artery disease stage III or IV),
    • Sickle cell disease,
  2. Patients presenting with a suspect thrombotic event related to catheter implantation
  3. Ongoing therapeutic anticoagulants (curative and preventive treatment) starting twenty four (24) hours or more before the D-dimer is measured
  4. Previous anticoagulant therapy stopped less than three (3) months before the D-dimer is measured
  5. Patients with previous DVT/PE occurred less than three (3) months from screening.
  6. Suspect thrombotic events in other locations at screening, including distal to the knee and upper extremity DVT (based on standard of care examinations)
  7. Patients with known tissue plasminogen activator (tPA) deficiency
  8. Patient participating or who has participated within one month of enrollment in another investigational study
  9. Major co-morbid condition(s) or other reasons that could limit the patient's ability to participate in the study or to comply with follow-up requirements, or impact the scientific integrity of the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To demonstrate the ability of STA Liatest DDi combined with a clinical pretest probability (PTP) to safely exclude pulmonary embolism or deep venous thrombosis in a 3 month follow-up
Time Frame: at 3 months
Occurence of pulmonary embolism or deep venous thrombosis during the 3 month follow-up after negative diagnosis (i.e. patients with PTP low/moderate and negative STA Liatest D-Di test)
at 3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
1. To analyse results homogeneity (inter-centers) in the group "positive D-dimer result and negative diagnosis" (descriptive statistics only). 2. To determine prevalence of VTE in PTP high patients based on imaging results
Time Frame: at 3 months
1. Prevalence of VTE in PTP high patients based on imaging results.
at 3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: GILLES PERNOD, MD PhD, University Hospital, Grenoble

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2011

Primary Completion (Actual)

March 1, 2016

Study Completion (Actual)

April 1, 2016

Study Registration Dates

First Submitted

October 12, 2010

First Submitted That Met QC Criteria

October 14, 2010

First Posted (Estimate)

October 15, 2010

Study Record Updates

Last Update Posted (Estimate)

August 5, 2016

Last Update Submitted That Met QC Criteria

August 4, 2016

Last Verified

August 1, 2016

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pulmonary Embolism

Subscribe